glp 1 drug market GLP-1 Drugs Size to Hit USD 132.79 Bn by 2035 New Demand in an Old
Description
5 In terms of safety, population-based data indicate a favorable neuropsychiatric profile for GLP-1R agonists, with a lower risk of suicidal ideation among adolescents using these drugs compared to controls
The S&P 500's 3 Best-Performing Stocks So Far in 2026 Last quarter, the company submitted its drug orforglipron, a new GLP-1 agonist, for obesity treatment in the United States and more than three dozen additional countries, with an expected domestic launch by mid-2026
The 2024 international PTDM consensus suggested GLP-1 RAs for PTDM patients with obesity and/or established CVDs
Neurobiol Aging (2018) 64:3343
110,111 Despite GSKs attempts to gain a competitive edge through low pricing, Tanzeum failed to achieve sufficient market acceptance
Cardiovasc Diabetol 20:205
